​

Karyopharm Therapeutics (KPTI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KPTI Stock Forecast

Karyopharm Therapeutics (KPTI) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $17.25, with a high of $28.00 and a low of $12.00. This represents a 91.67% increase from the last price of $9.00.

- $6 $12 $18 $24 $30 High: $28 Avg: $17.25 Low: $12 Last Closed Price: $9

KPTI Stock Rating

Karyopharm Therapeutics stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (70.00%), 4 Hold (20.00%), 2 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 2 4 14 Strong Sell Sell Hold Buy Strong Buy

KPTI Price Target Upside V Benchmarks

TypeNameUpside
StockKaryopharm Therapeutics91.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-29
Avg Price Target-$14.50$15.78
Last Closing Price$9.00$9.00$9.00
Upside/Downside-61.11%75.33%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26241--7
May, 26241--7
Apr, 26241--7
Mar, 26241--7
Feb, 26231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 06, 2026H.C. Wainwright$13.00$9.4138.15%44.44%
Apr 27, 2026Piper Sandler$16.00$8.6684.76%77.78%
Mar 09, 2026UBS$28.00$8.49229.80%211.11%
Dec 17, 2025Goldman Sachs$12.00$6.3389.57%33.33%
Nov 04, 2025Brian AbrahamsRBC Capital$19.00$5.60239.29%111.11%
Oct 13, 2025Robert BurnsH.C. Wainwright$15.00$5.50172.73%66.67%
Oct 09, 2025Robert W. Baird$21.00$5.90255.93%133.33%
Oct 08, 2025Leerink Partners$6.00$5.911.52%-33.33%
Jun 10, 2024Brian AbrahamsRBC Capital$3.00$0.95215.79%-66.67%
Jan 10, 2023Leerink Partners$5.00$2.8476.06%-44.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 09, 2026Cantor FitzgeraldOverweightOverweighthold
May 06, 2026H.C. WainwrightBuyBuyhold
Apr 27, 2026Piper SandlerOverweightOverweighthold
Mar 09, 2026Rodman & RenshawBuyinitialise
Feb 05, 2026Cantor FitzgeraldOverweightinitialise
Dec 17, 2025Piper SandlerOverweightOverweighthold
Nov 04, 2025RBC CapitalOutperformOutperformhold
Oct 13, 2025H.C. WainwrightNeutralBuyupgrade
Jul 16, 2025H.C. WainwrightBuyNeutraldowngrade
May 13, 2025BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$-35 $-27 $-19 $-11 $-3 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-24.75$-30.28$-18.79$-9.41$-17.93---
Avg Forecast$-2.62$-1.89$-1.20$-0.72$-0.74$-0.56$-0.02$-0.06
High Forecast$-2.24$-1.65$-1.16$-0.62$-0.42$-0.31$0.74$-0.05
Low Forecast$-3.00$-2.16$-1.24$-0.83$-1.20$-0.71$-0.72$-0.07
Surprise %844.66%1502.12%1465.83%1206.94%2322.97%---

Revenue Forecast

$100M $150M $200M $250M $300M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$209.82M$157.07M$146.03M$145.24M$146.07M---
Avg Forecast$133.12M$157.96M$147.69M$152.04M$165.50M$202.67M$293.88M$300.00M
High Forecast$147.98M$174.96M$170.61M$155.37M$187.45M$234.12M$295.17M$346.55M
Low Forecast$118.31M$142.55M$127.52M$148.71M$146.40M$174.99M$292.59M$259.02M
Surprise %57.62%-0.56%-1.12%-4.48%-11.74%---

Net Income Forecast

$-300M $-220M $-140M $-60M $20M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-124.09M$-165.29M$-143.10M$-76.42M$-196.04M---
Avg Forecast$-57.42M$-51.81M$-143.10M$-87.48M$-129.94M$-58.33M$-65.99M$-6.85M
High Forecast$-5.72M$2.78M$-12.03M$-70.66M$-47.61M$-35.00M$83.95M$-5.64M
Low Forecast$-109.11M$-106.41M$-274.17M$-94.79M$-137.16M$-81.66M$-81.95M$-8.24M
Surprise %116.12%219.01%--12.64%50.87%---

KPTI Forecast FAQ

Is Karyopharm Therapeutics stock a buy?

Karyopharm Therapeutics stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 4 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Karyopharm Therapeutics is a favorable investment for most analysts.

What is Karyopharm Therapeutics's price target?

Karyopharm Therapeutics's price target, set by 20 Wall Street analysts, averages $17.25 over the next 12 months. The price target range spans from $12 at the low end to $28 at the high end, suggesting a potential 91.67% change from the previous closing price of $9.

How does Karyopharm Therapeutics stock forecast compare to its benchmarks?

Karyopharm Therapeutics's stock forecast shows a 91.67% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Karyopharm Therapeutics over the past three months?

  • June 2026: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Karyopharm Therapeutics’s EPS forecast?

Karyopharm Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.56, marking a -96.88% decrease from the reported $-17.93 in 2025. Estimates for the following years are $-0.02 in 2027, and $-0.06 in 2028.

What is Karyopharm Therapeutics’s revenue forecast?

Karyopharm Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $202.67M, reflecting a 38.75% increase from the reported $146.07M in 2025. The forecast for 2027 is $293.88M, and $300M for 2028.

What is Karyopharm Therapeutics’s net income forecast?

Karyopharm Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-58.329M, representing a -70.25% decrease from the reported $-196M in 2025. Projections indicate $-65.989M in 2027, and $-6.853M in 2028.